Mizuho Securities USA LLC Buys 44,193 Shares of Boston Scientific Co. (NYSE:BSX)

Mizuho Securities USA LLC boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 46.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 139,685 shares of the medical equipment provider's stock after purchasing an additional 44,193 shares during the period. Mizuho Securities USA LLC's holdings in Boston Scientific were worth $12,477,000 as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. TFC Financial Management Inc. boosted its holdings in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 210 shares in the last quarter. Dunhill Financial LLC grew its stake in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 152 shares during the period. Global Wealth Strategies & Associates lifted its stake in shares of Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 250 shares during the period. West Oak Capital LLC acquired a new position in Boston Scientific during the fourth quarter worth about $29,000. Finally, Valley National Advisers Inc. boosted its stake in shares of Boston Scientific by 262.4% during the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 286 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

BSX has been the subject of a number of research analyst reports. Royal Bank of Canada raised their price target on Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. increased their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a report on Monday, December 16th. Argus set a $130.00 price target on shares of Boston Scientific in a research report on Tuesday, February 18th. Raymond James upped their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Finally, Piper Sandler raised their target price on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Two equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $108.91.

Boston Scientific Price Performance

Shares of NYSE BSX traded down $0.77 during trading on Wednesday, hitting $102.31. The company had a trading volume of 6,645,668 shares, compared to its average volume of 5,796,517. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The company has a market cap of $151.32 billion, a P/E ratio of 81.85, a PEG ratio of 2.79 and a beta of 0.77. The business's 50-day moving average is $101.99 and its 200 day moving average is $92.80. Boston Scientific Co. has a 52 week low of $66.80 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the sale, the executive vice president now owns 35,319 shares of the company's stock, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the transaction, the executive vice president now owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 137,302 shares of company stock worth $14,319,269 in the last quarter. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.